Omnicell reported higher profit and EBITDA for the third quarter of 2026 despite a small year-over-year decline in revenue. The healthcare technology company also said it updated its full-year outlook and pointed to growing customer interest in its next-generation medication-management platform.
- Revenue: $308 million, down $3 million, or 1%, from the third quarter of 2025. Revenue exceeded the high end of the company’s prior guidance range.
- Profit: GAAP net income rose to $11 million, or 24 cents per diluted share, from $5 million, or 12 cents, a year earlier. Non-GAAP net income increased to $27 million, or 58 cents per share, from $24 million, or 51 cents.
- EBITDA: Non-GAAP EBITDA was $45 million, compared with $41 million in the year-earlier quarter. Omnicell attributed the quarter’s performance to demand for its connected devices, favorable product and service margins, and cost discipline.
- Balance sheet: At September 30, Omnicell had $315 million in cash and cash equivalents and $169 million in debt, net of unamortized issuance costs. Total assets were $2.1 billion.
- 2026 outlook: The company said it updated its full-year guidance, but the text provided does not include the revised targets.
- Products and strategy: Chief Executive Randall Lipps cited momentum and a growing pipeline for the company’s next-generation platform, including Titan XT combined with its cloud-based OmniSphere platform. Omnicell says the offering is designed to improve medication-workflow efficiency, visibility and reliability.
The results show improved earnings and EBITDA alongside slightly lower revenue. Cash exceeded debt by $146 million at quarter-end. Omnicell’s stated strategic focus is on connecting medication-management systems and helping healthcare providers improve operational efficiency and address workforce pressures.